Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
US healthcare spending soars to over $5 trillion in 2024 - 2Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- 3Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- 4Space Condos to Lift Your Metropolitan Living
- 5Partake in the Outside: Senior-Accommodating Exercises for 2024
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- Limited Rain Chances in Brazil Boost Coffee Prices
- Reports: Germany plans expansion of foreign intelligence powers
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- Sweet Taste? Candy Fulfills You
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- Building an Individual Brand: Illustrations from Powerhouses
